BLTENasdaqPharmaceutical PreparationsFiscal year ends December 31
BELITE BIO, INC
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 31, 2026
$147.34+4.56 (+3.19%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
24.1%
9M of 39M shares
Institutional holders
81
22 new, 16 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
0 buys · 167 sales
Net sold $40.54M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Trehan Abhishek | 3,027,704 | 8.10% | 13G (passive) amendment | Dec 31, 2025 |
| Dr. Abhishek Trehan | 2,617,094 | 7.00% | 13G (passive) | Dec 3, 2025 |
| Lin Bioscience International Ltd. | 17,095,263 | 53.70% | 13G (passive) | Dec 31, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of BLTE | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Darwin Global Management, Ltd. | 3,077,219 | 7.82% | $456.59M | +19,807 | 12.14% |
| Paradigm Biocapital Advisors LP | 1,232,877 | 3.13% | $189.84M | +118,093 | 3.55% |
| Rtw Investments, LP | 715,332 | 1.82% | $110.15M | – | 0.94% |
| Millennium Management LLC | 494,564 | 1.26% | $76.16M | −75,524 | 0.03% |
| Maverick Capital Ltd | 396,311 | 1.01% | $61.03M | New | 0.54% |
| Eventide Asset Management, LLC | 390,829 | 0.99% | $60.18M | +33,179 | 0.80% |
| Deerfield Management Company, L.P. (Series C) | 357,199 | 0.91% | $55.00M | +53,186 | 0.57% |
| Holocene Advisors, LP | 251,035 | 0.64% | $38.66M | −243,460 | 0.09% |
| Logos Global Management LP | 250,000 | 0.64% | $38.50M | New | 1.66% |
| Morgan Stanley | 235,071 | 0.60% | $36.20M | +33,662 | 0.00% |
| UBS Group AG | 224,989 | 0.57% | $34.64M | −543,370 | 0.00% |
| Citadel Advisors LLC | 186,168 | 0.47% | $28.67M | +184,160 | 0.00% |
| Goldman Sachs Group Inc | 166,188 | 0.42% | $25.59M | +60,679 | 0.00% |
| Affinity Asset Advisors, LLC | 165,000 | 0.42% | $25.41M | +100,000 | 1.15% |
| Mpm Bioimpact LLC | 137,208 | 0.35% | $21.13M | +49,163 | 1.29% |
| Bank Of America Corp /De/ | 124,783 | 0.32% | $19.21M | +121,005 | 0.00% |
| Patient Square Capital LP | 110,000 | 0.28% | $16.94M | −6,684 | 2.62% |
| Duquesne Family Office LLC | 106,100 | 0.27% | $16.34K | – | 0.31% |
| Price T Rowe Associates Inc /Md/ | 105,859 | 0.27% | $16.30K | −175,946 | 0.00% |
| Jane Street Group, LLC | 65,801 | 0.17% | $10.13M | +53,579 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 81 | 9M | 24.1% | 22 / 28 | 22 / 16 | 2M | 1M |
| Q1 2026 | 75 | 9M | 23.2% | 28 / 26 | 15 / 21 | 3M | 1M |
| Q4 2025 | 69 | 7M | 18.3% | 40 / 17 | 10 / 4 | 6M | 1M |
| Q3 2025 | 34 | 2M | 5.8% | 16 / 12 | 5 / 0 | 2M | 0M |
| Q2 2025 | 18 | 0M | 0.2% | 6 / 6 | 5 / 6 | 0M | 0M |
| Q1 2025 | 18 | 0M | 0.4% | 7 / 5 | 5 / 11 | 0M | 0M |
| Q4 2024 | 22 | 0M | 0.7% | 9 / 6 | 5 / 2 | 0M | 0M |
| Q3 2024 | 15 | 0M | 0.2% | 6 / 5 | 2 / 2 | 0M | 0M |
| Q2 2024 | 11 | 0M | 0.5% | 2 / 2 | 6 / 2 | 0M | 0M |
| Q1 2024 | 11 | 0M | 0.2% | 0 / 2 | 8 / 6 | 0M | 0M |
| Q4 2023 | 17 | 0M | 0.5% | 12 / 3 | 1 / 2 | 0M | 0M |
| Q3 2023 | 7 | 0M | 0.3% | 3 / 2 | 1 / 2 | 0M | 1M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of BLTE | Value | % of fund | As of |
|---|---|---|---|---|---|
| T. Rowe Price Health Sciences Fund, Inc. | 80,462 | 0.20% | $12.39M | 0.10% | Jun 30, 2026 |
| Eventide Healthcare & Life Sciences Fund | 62,205 | 0.16% | $9.58M | 0.54% | Jun 30, 2026 |
| State Street(R) SPDR(R) Portfolio Emerging Markets ETF | 12,456 | 0.03% | $1.92M | 0.01% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index Fund | 6,727 | 0.02% | $969.90K | 0.00% | May 31, 2026 |
| Fidelity ZERO International Index Fund | 5,934 | 0.02% | $941.19K | 0.01% | Jul 31, 2026 |
| T. Rowe Price Health Sciences Portfolio | 5,400 | 0.01% | $831.52K | 0.11% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index ETF | 3,734 | 0.01% | $538.37K | 0.00% | May 31, 2026 |
| ActivePassive International Equity ETF | 3,713 | 0.01% | $535.34K | 0.05% | May 31, 2026 |
| Select Biotechnology Portfolio | 3,100 | 0.01% | $446.96K | 0.01% | May 31, 2026 |
| State Street(R) SPDR(R) S&P(R) China ETF | 3,068 | 0.01% | $472.43K | 0.11% | Jun 30, 2026 |
| Virtus Biotech Clinical Trials Etf | 2,250 | 0.01% | $356.87K | 0.77% | Jul 31, 2026 |
| Fidelity Flex International Index Fund | 2,090 | 0.01% | $331.49K | 0.01% | Jul 31, 2026 |
| Health Sciences Trust | 1,800 | 0.00% | $277.17K | 0.11% | Jun 30, 2026 |
| EQ/T.Rowe Price Health Sciences Portfolio | 1,400 | 0.00% | $215.58K | 0.12% | Jun 30, 2026 |
| Even Herd Long Short ETF | 1,282 | 0.00% | $197.41K | 0.33% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Hao-Yuan Chuang | Chief Financial Officer, Director | 28,600 | 0.07% | Sep 9, 2026 |
| Yu-Hsin Lin | Chief Executive Officer, Director | 87,644 | 0.22% | Sep 9, 2026 |
| Hendrik Peter Scholl | Chief Medical Officer | 24,904 | 0.06% | Jun 22, 2026 |
| Nathan L. Mata | Chief Scientific Officer | 440 | 0.00% | May 8, 2026 |
| Wan-Shan Chen | Director | 9,096 | 0.02% | Apr 13, 2026 |
| Xiao-Hui Chen | Director | 400 | 0.00% | Mar 18, 2026 |
| Ita Lu | Director | – | – | Mar 18, 2026 |
| John Michael Longo | Director | – | – | Mar 18, 2026 |
| Gary Clark Biddle | Director | – | – | Mar 18, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Yu-Hsin Lin Chief Executive Officer, Director | Sep 8, 2026 | Sale(10b5-1 plan) | −6,090 | $195.62 | $1.19M | 87,644 |
| Yu-Hsin Lin Chief Executive Officer, Director | Sep 8, 2026 | Sale(10b5-1 plan) | −2,400 | $194.33 | $466.39K | 93,734 |
| Yu-Hsin Lin Chief Executive Officer, Director | Sep 8, 2026 | Sale(10b5-1 plan) | −2,700 | $198.09 | $534.84K | 70,134 |
| Yu-Hsin Lin Chief Executive Officer, Director | Sep 8, 2026 | Sale(10b5-1 plan) | −8,752 | $197.36 | $1.73M | 72,834 |
| Yu-Hsin Lin Chief Executive Officer, Director | Sep 8, 2026 | Sale(10b5-1 plan) | −6,058 | $196.54 | $1.19M | 81,586 |
| Hao-Yuan Chuang Chief Financial Officer, Director | Sep 8, 2026 | Sale(10b5-1 plan) | −4,605 | $197.23 | $908.24K | 28,600 |
| Hao-Yuan Chuang Chief Financial Officer, Director | Sep 8, 2026 | Sale(10b5-1 plan) | −4,475 | $196.47 | $879.20K | 33,205 |
| Hao-Yuan Chuang Chief Financial Officer, Director | Sep 8, 2026 | Sale(10b5-1 plan) | −4,120 | $195.60 | $805.87K | 37,680 |
| Hao-Yuan Chuang Chief Financial Officer, Director | Sep 8, 2026 | Sale(10b5-1 plan) | −2,200 | $194.28 | $427.42K | 41,800 |
| Hao-Yuan Chuang Chief Financial Officer, Director | Sep 8, 2026 | Sale(10b5-1 plan) | −2,562 | $198.05 | $507.40K | 26,038 |
| Yu-Hsin Lin Chief Executive Officer, Director | Sep 4, 2026 | Sale(10b5-1 plan) | −4,209 | $192.54 | $810.40K | 104,245 |
| Yu-Hsin Lin Chief Executive Officer, Director | Sep 4, 2026 | Sale(10b5-1 plan) | −11,080 | $191.15 | $2.12M | 108,454 |
| Yu-Hsin Lin Chief Executive Officer, Director | Sep 4, 2026 | Sale(10b5-1 plan) | −600 | $190.39 | $114.23K | 119,534 |
| Yu-Hsin Lin Chief Executive Officer, Director | Sep 4, 2026 | Sale(10b5-1 plan) | −8,955 | $189.34 | $1.70M | 120,134 |
| Yu-Hsin Lin Chief Executive Officer, Director | Sep 4, 2026 | Sale(10b5-1 plan) | −3,045 | $188.26 | $573.25K | 129,089 |
| Yu-Hsin Lin Chief Executive Officer, Director | Sep 4, 2026 | Sale(10b5-1 plan) | −6,200 | $187.25 | $1.16M | 132,134 |
| Yu-Hsin Lin Chief Executive Officer, Director | Sep 4, 2026 | Sale(10b5-1 plan) | −7,800 | $186.32 | $1.45M | 138,334 |
| Yu-Hsin Lin Chief Executive Officer, Director | Sep 4, 2026 | Sale(10b5-1 plan) | −4,593 | $185.34 | $851.27K | 146,134 |
| Yu-Hsin Lin Chief Executive Officer, Director | Sep 4, 2026 | Sale(10b5-1 plan) | −6,252 | $184.52 | $1.15M | 150,727 |
| Yu-Hsin Lin Chief Executive Officer, Director | Sep 4, 2026 | Sale(10b5-1 plan) | −4,955 | $183.30 | $908.25K | 156,979 |
| Yu-Hsin Lin Chief Executive Officer, Director | Sep 4, 2026 | Sale(10b5-1 plan) | −3,413 | $182.50 | $622.87K | 161,934 |
| Yu-Hsin Lin Chief Executive Officer, Director | Sep 4, 2026 | Sale(10b5-1 plan) | −2,587 | $181.24 | $468.87K | 165,347 |
| Yu-Hsin Lin Chief Executive Officer, Director | Sep 4, 2026 | Sale(10b5-1 plan) | −2,635 | $180.29 | $475.06K | 167,934 |
| Yu-Hsin Lin Chief Executive Officer, Director | Sep 4, 2026 | Sale(10b5-1 plan) | −8,111 | $193.13 | $1.57M | 96,134 |
| Hao-Yuan Chuang Chief Financial Officer, Director | Sep 4, 2026 | Sale(10b5-1 plan) | −2,000 | $181.05 | $362.10K | 89,800 |
| Hao-Yuan Chuang Chief Financial Officer, Director | Sep 4, 2026 | Sale(10b5-1 plan) | −4,602 | $193.12 | $888.74K | 44,000 |
| Hao-Yuan Chuang Chief Financial Officer, Director | Sep 4, 2026 | Sale(10b5-1 plan) | −3,398 | $192.40 | $653.78K | 48,602 |
| Hao-Yuan Chuang Chief Financial Officer, Director | Sep 4, 2026 | Sale(10b5-1 plan) | −6,200 | $191.09 | $1.18M | 52,000 |
| Hao-Yuan Chuang Chief Financial Officer, Director | Sep 4, 2026 | Sale(10b5-1 plan) | −1,800 | $190.63 | $343.13K | 58,200 |
| Hao-Yuan Chuang Chief Financial Officer, Director | Sep 4, 2026 | Sale(10b5-1 plan) | −6,200 | $189.22 | $1.17M | 60,000 |
| Hao-Yuan Chuang Chief Financial Officer, Director | Sep 4, 2026 | Sale(10b5-1 plan) | −1,900 | $188.59 | $358.32K | 66,200 |
| Hao-Yuan Chuang Chief Financial Officer, Director | Sep 4, 2026 | Sale(10b5-1 plan) | −3,900 | $187.16 | $729.92K | 68,100 |
| Hao-Yuan Chuang Chief Financial Officer, Director | Sep 4, 2026 | Sale(10b5-1 plan) | −4,600 | $186.35 | $857.21K | 72,000 |
| Hao-Yuan Chuang Chief Financial Officer, Director | Sep 4, 2026 | Sale(10b5-1 plan) | −3,872 | $185.28 | $717.40K | 76,600 |
| Hao-Yuan Chuang Chief Financial Officer, Director | Sep 4, 2026 | Sale(10b5-1 plan) | −3,569 | $184.57 | $658.73K | 80,472 |
| Hao-Yuan Chuang Chief Financial Officer, Director | Sep 4, 2026 | Sale(10b5-1 plan) | −3,759 | $183.27 | $688.91K | 84,041 |
| Hao-Yuan Chuang Chief Financial Officer, Director | Sep 4, 2026 | Sale(10b5-1 plan) | −2,000 | $182.49 | $364.98K | 87,800 |
| Hao-Yuan Chuang Chief Financial Officer, Director | Sep 4, 2026 | Sale(10b5-1 plan) | −1,633 | $180.16 | $294.20K | 91,800 |
| Hao-Yuan Chuang Chief Financial Officer, Director | Aug 12, 2026 | Sale(10b5-1 plan) | −223 | $180.57 | $40.27K | 93,433 |
| Hao-Yuan Chuang Chief Financial Officer, Director | Aug 12, 2026 | Sale(10b5-1 plan) | −144 | $180.00 | $25.92K | 93,656 |
| Yu-Hsin Lin Chief Executive Officer, Director | Aug 12, 2026 | Sale(10b5-1 plan) | −142 | $180.00 | $25.56K | 170,792 |
| Yu-Hsin Lin Chief Executive Officer, Director | Aug 12, 2026 | Sale(10b5-1 plan) | −223 | $180.57 | $40.27K | 170,569 |
| Hendrik Peter Scholl Chief Medical Officer | Jun 18, 2026 | Sale | −96 | $143.90 | $13.81K | 24,904 |
| Hendrik Peter Scholl Chief Medical Officer | Jun 18, 2026 | Sale | −4,861 | $145.43 | $706.94K | 16,295 |
| Hendrik Peter Scholl Chief Medical Officer | Jun 18, 2026 | Sale | −1,199 | $146.24 | $175.34K | 15,096 |
| Hendrik Peter Scholl Chief Medical Officer | Jun 18, 2026 | Sale | −96 | $147.11 | $14.12K | 15,000 |
| Hendrik Peter Scholl Chief Medical Officer | Jun 18, 2026 | Sale | −3,748 | $144.66 | $542.19K | 21,156 |
| Hendrik Peter Scholl Chief Medical Officer | Jun 16, 2026 | Sale | −1,897 | $143.55 | $272.31K | 26,035 |
| Hendrik Peter Scholl Chief Medical Officer | Jun 16, 2026 | Sale | −450 | $142.20 | $63.99K | 27,932 |
| Hendrik Peter Scholl Chief Medical Officer | Jun 16, 2026 | Sale | −100 | $141.83 | $14.18K | 28,382 |
| Hendrik Peter Scholl Chief Medical Officer | Jun 16, 2026 | Sale | −540 | $140.58 | $75.91K | 28,482 |
| Hendrik Peter Scholl Chief Medical Officer | Jun 16, 2026 | Sale | −3,140 | $139.57 | $438.25K | 29,022 |
| Hendrik Peter Scholl Chief Medical Officer | Jun 16, 2026 | Sale | −1,035 | $145.02 | $150.10K | 25,000 |
| Hendrik Peter Scholl Chief Medical Officer | Jun 16, 2026 | Sale | −2,054 | $137.61 | $282.65K | 32,946 |
| Hendrik Peter Scholl Chief Medical Officer | Jun 16, 2026 | Sale | −784 | $138.18 | $108.33K | 32,162 |
| Nathan L. Mata Chief Scientific Officer | May 7, 2026 | Sale(10b5-1 plan) | −226 | $152.45 | $34.45K | 440 |
| Nathan L. Mata Chief Scientific Officer | May 7, 2026 | Sale(10b5-1 plan) | −9 | $155.25 | $1.40K | 0 |
| Nathan L. Mata Chief Scientific Officer | May 7, 2026 | Sale(10b5-1 plan) | −428 | $153.56 | $65.72K | 12 |
| Nathan L. Mata Chief Scientific Officer | May 7, 2026 | Sale(10b5-1 plan) | −3 | $154.61 | $464 | 9 |
| Nathan L. Mata Chief Scientific Officer | May 6, 2026 | Sale(10b5-1 plan) | −100 | $156.00 | $15.60K | 666 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Peter Scholl Hendrik Officer | Oct 1, 2026 | 4,000 | $679.28K | Oct 1, 2026 | RSU Vesting |
| Chuang Hao-Yuan Officer, Director | Aug 12, 2026 | 93,800 | $16.66M | Aug 12, 2026 | ESOP Exercise |
| Lin Yu-Hsin CEO, Chairman | Aug 12, 2026 | 126,800 | $22.52M | Aug 12, 2026 | ESOP Exercise |
| Hendrick P. Scholl Dr. Affiliate | Jun 18, 2026 | 10,000 | $1.48M | Jun 18, 2026 | Vested RSUs |
| Hendrick P. Scholl Dr. Affiliate | Jun 16, 2026 | 10,000 | $1.44M | Jun 16, 2026 | Vested RSUs |
| L. Mata Nathan Officer | Apr 15, 2026 | 16,666 | $2.87M | Apr 15, 2026 | Stock Option Exercise |
| Chuang Hao-Yuan Officer, Director | Apr 9, 2026 | 100,000 | $17.87M | Apr 9, 2026 | ESOP Exercise |
| Lin Yu-Hsin CEO, Chairman | Apr 9, 2026 | 136,000 | $24.31M | Apr 9, 2026 | ESOP Exercise |
| Shan Chen Wan affiliate | Apr 9, 2026 | 10,196 | $2.22M | Apr 9, 2026 | Exercise and Hold of Stock Options |
| Shan Chen Wan Affiliate | Oct 17, 2025 | 9,550 | $1.16M | Oct 17, 2025 | NQ Stock Award |
| Shan Chen Wan affiliate | Oct 16, 2025 | 1,050 | $89.25K | Oct 16, 2025 | NQ Stock Award |
| Shan Chen Wan affiliate | Oct 14, 2025 | 1,050 | $84.00K | Oct 13, 2025 | NQ Stock Award |
| Chuang Hao-Yuan Officer, Director | Oct 14, 2025 | 70,054 | $5.59M | Oct 13, 2025 | Stock Option Exercise |
| Lin Yu-Hsin CEO, Chairman | Sep 18, 2025 | 96,950 | $7.08M | Sep 18, 2025 | Employee Stock Option Exercise |
| L. Mata Nathan Officer | Aug 21, 2025 | 30,000 | $1.90M | Aug 21, 2025 | Stock Option Exercise |